Related Experiment Video
Updated: Jun 22, 2026
06:16
Tracking Fibrinolysis of Chandler Loop-Formed Whole Blood Clots Under Shear Flow in An In-Vitro Thrombolysis Model
Published on: April 19, 2024
Recent developments in thrombin-activatable fibrinolysis inhibitor research.
Pauline F Marx1, Chantal J N Verkleij, Mercedes Valls Seron
1Department of Experimental Vascular Medicine, G1-145, Academic Medical Center, P.O. Box 22660, 1100 DD Amsterdam, The Netherlands. p.f.marx@amc.uva.nl
Mini Reviews in Medicinal Chemistry
|June 19, 2009
Summary
Thrombin-activatable fibrinolysis inhibitor (TAFI) links blood coagulation and fibrinolysis. Recent research covers TAFI structures, inhibitors, and its roles beyond hemostasis.
Area of Science:
- Biochemistry
- Molecular Biology
- Hematology
Background:
- Thrombin-activatable fibrinolysis inhibitor (TAFI) is a key regulator connecting coagulation and fibrinolysis.
- Understanding TAFI's function is crucial for managing hemostatic disorders.
Purpose of the Study:
- To review recent advancements in TAFI research.
- To discuss the implications of these findings for understanding hemostasis and other biological systems.
Main Methods:
- Literature review of recent studies on TAFI.
- Analysis of structural, biochemical, and physiological data related to TAFI.
Main Results:
- Elucidation of TAFI crystal structures providing insights into its mechanism.
- Development of novel small molecule inhibitors targeting TAFI.
- Identification of TAFI's involvement in systems beyond hemostasis.
Conclusions:
- TAFI is a multifaceted protein with implications for thrombosis and potentially other diseases.
- Further research into TAFI inhibitors and non-hemostatic roles is warranted.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:17Intracellular Signaling Affects Focal Adhesions
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...